ADAR1 Capital Management LLC Acquires New Stake in BioMarin Pharmaceutical Inc. $BMRN

Key Points

• ADAR1 Capital Management acquired 49,000 BioMarin shares during the second quarter, valued at approximately $2.8 million. Institutional investors collectively own 98.71% of BMRN’s outstanding stock.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $88.83, despite several firms recently lowering their targets.
• BioMarin reported quarterly earnings of $1.20 per share, beating estimates of $0.95, while revenue rose 20% year over year to $989.71 million. Shares opened at $66.12, within a 12-month range of $49.26 to $70.98.

ADAR1 Capital Management LLC acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 49,000 shares of the biotechnology company's stock, valued at approximately $2,804,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. NewEdge Advisors LLC boosted its position in BioMarin Pharmaceutical by 11.5% in the 1st quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company's stock valued at $266,000 after buying an additional 388 shares during the period. Empowered Funds LLC increased its position in shares of BioMarin Pharmaceutical by 207.4% during the first quarter. Empowered Funds LLC now owns 12,023 shares of the biotechnology company's stock worth $850,000 after acquiring an additional 8,112 shares during the period. Focus Partners Wealth raised its stake in shares of BioMarin Pharmaceutical by 70.2% during the first quarter. Focus Partners Wealth now owns 11,817 shares of the biotechnology company's stock valued at $835,000 after acquiring an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in BioMarin Pharmaceutical by 33.0% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,439 shares of the biotechnology company's stock worth $244,000 after purchasing an additional 1,102 shares during the period. Finally, Invesco Ltd. raised its position in BioMarin Pharmaceutical by 23.5% during the 2nd quarter. Invesco Ltd. now owns 618,835 shares of the biotechnology company's stock valued at $34,017,000 after purchasing an additional 117,617 shares in the last quarter. Hedge funds and other institutional investors own 98.71% of the company's stock.

Analyst Ratings Changes

BMRN has been the topic of a number of recent research reports. Sanford C. Bernstein dropped their price target on BioMarin Pharmaceutical from $94.00 to $82.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 5th. Canaccord Genuity Group lifted their price objective on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company a "buy" rating in a report on Monday, August 10th. Royal Bank Of Canada lowered their price objective on shares of BioMarin Pharmaceutical from $66.00 to $62.00 and set a "sector perform" rating for the company in a research note on Tuesday, July 7th. Bank of America dropped their target price on shares of BioMarin Pharmaceutical from $85.00 to $80.00 and set a "buy" rating on the stock in a report on Tuesday, May 19th. Finally, The Goldman Sachs Group assumed coverage on shares of BioMarin Pharmaceutical in a research report on Monday, May 11th. They set a "neutral" rating and a $69.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $88.83.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN stock opened at $66.12 on Wednesday. BioMarin Pharmaceutical Inc. has a 12-month low of $49.26 and a 12-month high of $70.98. The business's fifty day simple moving average is $61.07 and its 200-day simple moving average is $57.99. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56. The company has a market cap of $12.80 billion, a PE ratio of 178.70, a PEG ratio of 0.47 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.95 by $0.25. The firm had revenue of $989.71 million during the quarter, compared to analysts' expectations of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The business's quarterly revenue was up 20.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Analysts expect that BioMarin Pharmaceutical Inc. will post 4.1 earnings per share for the current fiscal year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source